Actualités

WWW's Q2 beat and raised 2026 outlook reflect strong Merrell and Saucony momentum, brand gains and improving operating performance.

In early August 2026, FIGS, Inc. reported second-quarter sales of US$196.62 million and net income of US$28.38 million, raised its full-year 2026 revenue growth guidance to about 20% versus 2025, and expanded its share repurchase authorization to US$200 million after already buying back 12,453,520 shares for US$80.8 million. The combination of faster revenue and earnings growth, higher full-year expectations, and an enlarged buyback program underscores management’s confidence in FIGS’...

TPR surpasses Q4 earnings estimates as Coach drives growth, margins expand and cash generation strengthens despite tariff headwinds.

EAT's Q4 EPS rises 23.3% as Chili's sales and traffic grow, margins expand and fiscal 2027 guidance calls for continued revenue and earnings growth.

CAVA beats Q2 earnings and revenue estimates as traffic and unit growth lift sales, though higher food, labor and delivery costs pressure margins.

FIGS' accelerating growth and improving margins support its momentum, but a rich valuation raises the bar for further gains.

FIGS delivers 28.8% Q2 revenue growth and higher margins, but its premium valuation raises the bar for continued momentum.

Shares of healthcare apparel company Figs (NYSE:FIGS) jumped 28.5% in the afternoon session after the healthcare apparel company reported second-quarter 2026 results that beat Wall Street on both revenue and adjusted earnings. FIGS is converting more customers into bigger baskets: active customers rose 13% to 3.1 million, average order value climbed to $127, and adjusted EPS of $0.11 cleared the $0.07 consensus as margins expanded sharply. Management tied the $196.6 million revenue print (+28.8%

PZZA's Q2 earnings and revenues beat estimates, but shares sink 17.2% as weaker comps, reduced 2026 guidance and a dividend suspension weigh.

Figs (NYSE:FIGS) shares surged 27. 7% in premarket trading after the healthcare apparel company reported second-quarter 2026 results that comfortably exceeded Wall Street expectations.

Figs (FIGS) delivered earnings and revenue surprises of +57.14% and +5.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Healthcare apparel company Figs (NYSE:FIGS) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 28.8% year on year to $196.6 million. Its GAAP profit of $0.15 per share was significantly above analysts’ consensus estimates.

SHAK's Q2 earnings beat estimates and revenues rose 17.2% YoY, but beef inflation and higher costs pressured margins.

BROS tops Q2 estimates with strong comps and expansion, lifts 2026 outlook as new shops and traffic growth fuel momentum.

FIGS heads into Q2 earnings with product innovation, global expansion and demand momentum in focus, while tariffs and freight costs may have pressured margins.

CMG's second-quarter results reflect benefits from positive comparable sales, restaurant expansion and stronger digital engagement.

YUM tops earnings estimates as Taco Bell's strong sales and global expansion help offset softer Pizza Hut performance.

SBUX's shares jump after fiscal third-quarter adjusted earnings beat estimates, comparable sales rise and management lifts fiscal 2026 guidance.

FIGS stock has returned 77.6% over the past year, yet the valuation checks are sending mixed signals as the Discounted Cash Flow (DCF) intrinsic value estimate points to some upside while earnings based multiples lean the other way. Over the last 12 months FIGS has delivered a 77.6% share price gain, which puts added focus on whether that rerating is backed up by fundamentals. Recent optimism around earnings prospects, highlighted by an analyst upgrade, can support the intrinsic value case...

Figs (FIGS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

FIGS' stronger revenue outlook and customer growth support the bull case, but its big rally, richer valuation and cost pressure complicate the buy call.

A number of stocks jumped in the afternoon session after oil prices fell on hopes of a US-Iran peace deal.

If you are wondering whether FIGS at US$11.66 is offering good value or just pricing in a lot of optimism, the next steps are all about putting some structure around that question. The stock has returned 2.0% over the last week, 0.3% over the past month, 2.4% year to date, 124.2% over the last year, 34.8% over three years and a decline of 65.7% over five years, giving you a mix of strong recent gains and a longer term reset to think about. Recent headlines have focused on FIGS as a...

In early June 2026, FIGS reported quarterly results that surpassed analyst expectations, highlighting broad-based sales growth, improving margins, and strong cash flow across its healthcare apparel business. These results underline how FIGS’ product innovation and disciplined operations are supporting both reinvestment in growth initiatives and ongoing returns to shareholders. Now we’ll explore how this stronger-than-expected profitability performance may reshape FIGS’ existing investment...

One company powers healthcare apparel with direct sales and rapid growth, while the other scales global basics with steady cash flow and lower valuations.

A number of stocks jumped in the afternoon session after easing pressure in the bond market and a pullback in oil prices boosted investor sentiment for consumer-facing companies.

FIGS, Inc. (NYSE:FIGS) is one of the 8 Best Small Cap US Stocks to Buy. On May 7, 2026, FIGS, Inc. (NYSE:FIGS) reported Q1 EPS of 3c, versus the consensus estimate of 2c. Revenue totaled $159.9M, versus the consensus estimate of $153.14M. Active customers as of March 31 increased 12.2% year over year to 3.0M, […]

Figs (FIGS) delivered earnings and revenue surprises of +125.56% and +5.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

FIGS, GAP and CPRI enter the earnings season with strong momentum, margin discipline and positive ESPs, signaling potential earnings surprises.

BLDR Q1 EPS misses estimates as sales fall 10%. Sales, however, beat forecasts. The new 2026 outlook turns cautious while buybacks expand.